Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Experimental drug aims to tame painful leprosy Flare-Ups

NCT ID NCT07172659

Summary

This study is testing an unapproved drug called dovramilast to see if it works better and is safer than current treatments for severe skin flare-ups caused by leprosy. Researchers will compare two doses of dovramilast against standard care in 45 adults over 12 weeks. The main goal is to see if the new drug can significantly reduce the number of painful skin lesions without needing additional rescue medication.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ERYTHEMA NODOSUM LEPROSUM are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Centre de Dépistage de Traitement de la Lèpre et de l'Ulcère de Burulli

    Abomey-Calavi, Benin

  • Chr de Divo

    Divo, Côte d’Ivoire

  • Harborview Medical Center, University of Washington

    Seattle, Washington, 98104, United States

  • Philippine General Hospital, University of the Philippines, Manila

    Manila, Philippines

  • Universitas Gadjah Mada

    Yogyakarta, Indonesia

  • University of Southern California

    Los Angeles, California, 90007, United States

Conditions

Explore the condition pages connected to this study.